Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00173056
Status:
UNKNOWN
Last Update Posted:
2007-11-26
First Post:
2005-09-12
Brief Title:
The Factors Predicting Change of Peritoneal Transport Characters in Peritoneal Dialysate
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2004-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Peritoneal fibrosis PF is one of the most serious complications after long-term continuous ambulatory peritoneal dialysis CAPD Human peritoneal fibroblast HPFB and extracellular matrix ECM deposition is the most possible causes leading to PF ECM are mainly synthesized from HPFB and human peritoneal mesothelial cells HPMC In the PF process there is decrement in the quantity of HPMC loss of permeability for lower molecules and eventually ultrafiltration failure This phenomena will result in technique failure
High glucose content of the dialysate and peritonitis have been claimed as major stimulants to the development of PF In each episode of peritonitis the number of HPMC will decrease On the other hand ECM production will be reinforced by the inflammatory cytokines secreted by the white cells or HPMC per se High glucose dialysate will induce the above process with more chronic stimulation and PF followed by technique failure is inevitable
Peritoneal fibrosis is definitively diagnosed with peritoneal biopsy but this is inconvenient for most patients Besides pathology changes will be noted only after a substantial loss of peritoneal function The peritoneal equilibration test PET is usually used as the index of peritoneal function However in the chronic process PET change is also slow and is unable to be a parameter for treatment outcome In this study the factors predicting PET change will be searched and they could be an index for evaluation and even a marker of preventing or treating PF
In this project peritoneal dialysis PD dialysate will be collected during an annual PET in each PD patient in the National Taiwan University Hospital NTUH Some cytokines that will be measured include vasculoendothelial growth factor hyaluronan transforming growth factor-β procollagen and cancer antigen-125 The same test and measurement will be performed during PET in the next year The factors which affect PET results will be analyzed such as cytokines glucose exposure peritonitis incidence PD duration gender age The investigators will try to find a convenient acute reactive marker for preventing or treating PF to monitor the PET change clinically
High glucose content of the dialysate and peritonitis have been claimed as major stimulants to the development of PF In each episode of peritonitis the number of HPMC will decrease On the other hand ECM production will be reinforced by the inflammatory cytokines secreted by the white cells or HPMC per se High glucose dialysate will induce the above process with more chronic stimulation and PF followed by technique failure is inevitable
Peritoneal fibrosis is definitively diagnosed with peritoneal biopsy but this is inconvenient for most patients Besides pathology changes will be noted only after a substantial loss of peritoneal function The peritoneal equilibration test PET is usually used as the index of peritoneal function However in the chronic process PET change is also slow and is unable to be a parameter for treatment outcome In this study the factors predicting PET change will be searched and they could be an index for evaluation and even a marker of preventing or treating PF
In this project peritoneal dialysis PD dialysate will be collected during an annual PET in each PD patient in the National Taiwan University Hospital NTUH Some cytokines that will be measured include vasculoendothelial growth factor hyaluronan transforming growth factor-β procollagen and cancer antigen-125 The same test and measurement will be performed during PET in the next year The factors which affect PET results will be analyzed such as cytokines glucose exposure peritonitis incidence PD duration gender age The investigators will try to find a convenient acute reactive marker for preventing or treating PF to monitor the PET change clinically
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None